Lantern Pharma uses GenAI agents to cut rare cancer drug research from months to minutes speeding drug discovery.

Lantern Pharma showcased how GenAI can reshape oncology drug discovery through its withZeta.ai platform. The system combines multiple GenAI agents, scientific databases, and molecular design tools into one research workflow. Instead of searching manually through scattered studies, researchers can ask complex cancer questions in natural language. The platform then analyzes clinical trials, biomarkers, failed studies, and drug interactions in real time.

The biggest challenge Lantern addresses is research fragmentation. Rare cancer data sits across journals, trials, and disconnected databases. Traditional analysis often takes weeks and requires large specialist teams. WithZeta.ai compresses this process into minutes. The platform reviewed more than 100 research sources during live demonstrations. It also generated ranked drug candidates, identified trial risks, and proposed new molecular structures. Importantly, the system explains how conclusions are reached, reducing the “black box” problem common in GenAI systems.

Lantern also tackles another major industry problem: slow molecule design. Drug discovery usually involves expensive trial-and-error workflows. WithZeta.ai iterates molecular designs automatically while testing properties like toxicity, bioavailability, and blood-brain barrier penetration. The platform can also estimate development budgets and clinical timelines instantly. This allows biotech teams to evaluate commercial feasibility much earlier.

The company positions withZeta.ai as a collaborative GenAI workspace for scientists. Researchers can share knowledge graphs, export reports, and run multi-agent investigations together. Lantern believes this model could become the operating system for oncology R&D, especially for rare cancers where expertise and data remain limited.

Why it matters
Lantern Pharma demonstrates how GenAI is shifting from research support to scientific co-development.

• Solves the enterprise problem of fragmented biomedical knowledge and slow analysis.
• Reduces drug discovery timelines from months to minutes.
• Improves transparency by showing how GenAI reaches scientific conclusions.
• Helps biotech firms test commercial viability earlier in development.
• Creates collaborative GenAI workflows instead of isolated research tools.
• Shows how agentic GenAI can support highly specialized industries beyond chatbots.